Cargando…

Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System

Introduction: Antibiotic use is an important risk factor for Clostridium difficile infection (CDI). Prior meta-analyses have identified antibiotics and antibiotic classes that pose the greatest risk for CDI; however, CDI epidemiology is constantly changing and contemporary analyses are needed. Objec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Chengwen, Reveles, Kelly R., Obodozie-Ofoegbu, Obiageri O., Frei, Christopher R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566741/ https://www.ncbi.nlm.nih.gov/pubmed/31217729 http://dx.doi.org/10.7150/ijms.30739

Ejemplares similares

Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019)

2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
por: Groff, Lindsey, et al.
Publicado: (2018)

1881. Empiric Pseudomonal Monotherapy vs. Combination Therapy for Community-Onset Pneumonia in Older Adults
por: Obodozie-Ofoegbu, Obiageri, et al.
Publicado: (2018)

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2021)

1977. Comparing Acute Kidney Injury Risk among Antibiotic Classes: A Study of the FDA Adverse Event Reporting System (FAERS)
por: Patek, Taylor M, et al.
Publicado: (2019)

Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)

2296. Hypoglycemia Risk with Antibiotics: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)
por: Kennedy, Kaitlin E, et al.
Publicado: (2019)

3542 Torsade de pointes/QT prolongation risks with antibiotics: A contemporary analysis of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019)

Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics
por: Evoy, Kirk E, et al.
Publicado: (2019)

Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs
por: Lucero, Kana Tai, et al.
Publicado: (2023)

Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals
por: Delgado, Andrew, et al.
Publicado: (2017)

National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014
por: Reveles, Kelly R., et al.
Publicado: (2017)

Clostridium difficile infection health disparities by race among hospitalized adults in the United States, 2001 to 2010
por: Argamany, Jacqueline R., et al.
Publicado: (2016)

The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) Database
por: Clifford, Kalin M., et al.
Publicado: (2022)

Clostridium difficile and Antibiotic-associated Diarrhea
por: Bhattacharyya, Mahuya, et al.
Publicado: (2020)

Antibiotics Associated With Clostridium difficile Infection
por: Rafey, Abdur, et al.
Publicado: (2023)

National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals
por: Pechal, Ashley, et al.
Publicado: (2016)

Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis
por: Rao, Shasha, et al.
Publicado: (2016)

Intrinsic Class D β-Lactamases of Clostridium difficile
por: Toth, Marta, et al.
Publicado: (2018)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

513. Effectiveness of Pulsed Xenon Ultraviolet Light Disinfection System to Decrease Clostridium difficile Infections at the South Texas Veterans Health Care System
por: Cepeda, Victor, et al.
Publicado: (2018)

Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data
por: Nevin, Remington L., et al.
Publicado: (2017)

2388. High-risk antibiotics associated with Clostridioides difficile infection: a national, multicenter analysis
por: Young, Eric H, et al.
Publicado: (2019)

The rate and importance of Clostridium difficile in colorectal cancer patients
por: Jahani-Sherafat, Somayeh, et al.
Publicado: (2019)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
por: Kan, Yusuke, et al.
Publicado: (2021)

Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection
por: Chilton, C. H., et al.
Publicado: (2016)

Effect of Bifidobacterium breve in Combination With Different Antibiotics on Clostridium difficile
por: Yang, Jingpeng, et al.
Publicado: (2018)

Incidence of Clostridium difficile Infection After Sepsis Protocol Antibiotics
por: LaFave, Jordan, et al.
Publicado: (2019)

Community acquired Clostridium difficile in an infant without antibiotic exposure
por: Singh, Jaspreet, et al.
Publicado: (2020)

Early diagnosis and antibiotic treatment for fulminant Clostridium difficile infection
por: Fukushima, Kazutaka, et al.
Publicado: (2020)

A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class
por: Hoffman, Keith B., et al.
Publicado: (2012)

Characteristics of the Clostridium difficile cell envelope and its importance in therapeutics
por: Kirk, Joseph A., et al.
Publicado: (2016)

Importance of Glutamate Dehydrogenase (GDH) in Clostridium difficile Colonization In Vivo
por: Girinathan, Brintha Parasumanna, et al.
Publicado: (2016)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Etiology of Infectious Diarrhea in Patients Tested for Clostridium difficile: If It Isn’t Clostridium difficile, What Is It?
por: Kwon, Jennie H, et al.
Publicado: (2017)

Evaluation of the Xpert Clostridium difficile Assay for the Diagnosis of Clostridium difficile Infection
por: Shin, Saeam, et al.
Publicado: (2012)

Patient and Strain Characteristics Associated With Clostridium difficile Transmission and Adverse Outcomes
por: Martin, Jessica S H, et al.
Publicado: (2018)

Importance of Toxin A, Toxin B, and CDT in Virulence of an Epidemic Clostridium difficile Strain
por: Kuehne, Sarah A., et al.
Publicado: (2014)

Prevalence and Health Outcomes of Clostridioides difficile Infection During the Coronavirus Disease 2019 Pandemic in a National Sample of United States Hospital Systems
por: Reveles, Kelly R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mggrg5mvkigp87tv75uh6m9m3m